Low-Frequency REpetitive TRanscranial Magnetic Stimulation Combined With Endovascular Treatment in ACute Ischemic StrokE

Inclusion Criteria: 1. 18 - 80 years, male or female; 2. Clinically diagnosed as acute anterior ischemic stroke, artery occlusion occurred at the terminal of the intracranial carotid artery, T-shaped bifurcation or M1 segment of the middle cerebral artery; 3. Within 24 hours of stroke onset; 4. Eligible for other imaging indications for bridging therapy or direct mechanical thrombectomy: ASPECTS ≥6 certified by the latest brain CT imaging; Patients within 6-16 hours after stroke onset should meet the mismatch criteria, which was defined as infarction core volume \<70 ml, mismatch ratio ≥1.8 and the ischemic volume \> 15 ml (DEFUSE-3 Criteria); or NIHSS score ≥ 10 with infarction -core volume \< 31 cm3, or NIHSS score ≥ 20 with infarction core volume ≤ 51 cm3 (DAWN Criteria); Patients within 16-24 hours after stroke onset should meet the mismatch criteria, which was defined as NIHSS score ≥ 10 with infarction-core volume \< 31 cm3, or NIHSS score ≥ 20 with infarction-core volume ≤ 51 cm3 (DAWN Criteria); 5. Planned to receive bridging therapy (endovascular therapy after intravenous alteplase) or direct endovascular therapy; 6. Pre-morbid modified Rankin Scale ≤1; 7. 6 ≤ NIHSS ≤ 25 before endovascular therapy; 8. Signed informed consent from subjects or legally authorized representatives Exclusion Criteria: 1. TMS contraindications include metallic foreign bodies in the head, pacemaker, implantable drug pumps, cochlear implants, etc. 2. Epilepsy or history of epilepsy, intracranial hypertension, tumor and other serious neurological disorders; 3. Midline displacement and brain parenchymal mass effect seen in head CT and other images; 4. Head CT or MRI showed bilateral acute cerebral infarction; 5. CT or MRI showed a large area of infarction (\> 1/3 of the area supplied by middle cerebral artery); 6. Evidence of acute intracranial hemorrhage; 7. Before the bridging therapy, other thrombolytic drugs besides alteplase or tenecteplase were used; 8. A history of congenital or acquired hemorrhagic disease, coagulation factor deficiency, or thrombocytopenia disease; 9. After blood pressure control, the systolic blood pressure was still ≥180 mmHg or the diastolic blood pressure was ≥110 mmHg; 10. Known recent or current serum creatinine exceeding 1.5 times the upper limit of normal or estimated glomerular filtration rate (EGFR) \< 60 mL/min; 11. Patients during pregnancy or lactation and within 90 days of planned pregnancy; 12. Patients with severe mental disorders or dementia who can not cooperate with informed consent and follow-up; 13. Patients with malignancy or severe systemic disease and expected survival of less than 90 days; 14. Participants in other clinical intervention studies within 30 days before randomization or who were participating in other clinical intervention studies.